UK contracting group Pharmaceutical Development Services (PDS) has set up an office in North Carolina, US to court North America pharma firms for the European development sector.
US contractor Azopharma has added new GMP quality cytotoxics and high-potency manufacturing capacity at its facility in Hollywood, South Florida in a bid to strengthen its position in the trial materials sector.
Drug delivery specialist Hospira has set up a “biologics clock” that counts the amount spent on cell culture-derived medications in the US in a bid to highlight the potential savings greater use of generics could provide.
US contractor MeadWestvaco (MWV) claims the latest addition to its Shellpack range, the Shellpak-170, offers drugmakers more options for adherence promotion blister packaging.
The US contract manufacturing sector is strong enough to bounce back from any short-term slow down caused by the credit crisis, according to a new report by Frost & Sullivan (F&S).
Alastair Riddell, CEO of UK firm Stem Cell Sciences (SCS), says the US governments’ reversal of the ban on federally funded stem cell research “opens up a market that was inhibited, restrained and impeded under the Bush administration.”
The issue of transparency in clinical research has raised its head again with a new study suggesting the results of Phase I trials are less likely to be published compared to other types of studies.
US biotechnology company Cel-Sci is hoping to offer contract manufacturing to pharmaceutical partners from its new facility in Baltimore, as it tries to raise money to support the clinical development of its cancer immunotherapy Multikine.
The market for packaging machinery is set to grow 5 per cent a year and be worth $40bn (€30.3bn) by 2012, driven partly by a hike in demand for drug products in “pharmerging” economies, according to a new industry report.
There is no formal requirement to inform clinical trial participants of the results of the study, a situation which can leave them “confused, frustrated and, in some cases, lacking information that may be important to their health,” according to a report...
Parexel has made a bold foray into the troublesome arena of stroke drug development via an alliance with Safe Implementation of Treatments in Stroke (SITS) International, an international network of clinical sites geared up to recruit stroke patients.
UK drug major GSK is cutting approximately 1,000 US sales jobs by the end of 2008 as it reorganizes to compete in the increasingly tough pharmaceutical market.
Clinical trials that support the effectiveness of drugs filed for approval in the US are more likely to be published than those that are less supportive, according to researchers at the University of California at San Francisco.
Pharmatek Laboratories has opened its highly-potent and cytotoxic facility located in San Diego, US, just over a year after announcing its move into this growth area of contract manufacturing.
APP Pharmaceuticals has bought additional facilities at a site in Grand Island, New York seizing the opportunity created by Astellas Manufacturing’s decision to shift production of its dermatitis drug Protopic to Japan.
DSM Pharmaceuticals now has its new commercial scale cytotoxic
contract manufacturing facility up and running, and is only the
second company in the US to offer such a service on this scale.
A new, more patient-friendly presentation of the growth hormone
treatment Omnitrope (rDNA somatropin) has been launched in the US
by Sandoz, the generics division of Swiss-based Novartis.
The US launch of the hotly touted, next-generation mouthwash,
Decapinol, has stalled following the decision to reformulate the US
product as a "precautionary measure".
Lab equipment specialist Sotax has announced the creation of a new contract research organisation (CRO) focused exclusively on dissolution testing services.
India's Reliance Life Sciences (RLS) is planning an acquisition in
Europe or in the US joining the slow infiltration of Indian firms
cementing themselves in Western markets.
In a round-up of motley pharmaceutical services contracts,
Outsourcing-Pharma takes a look at recent news involving Movianto,
PDI, inVentiv Health and Exel.
Veeda Clinical Research, an Anglo-Indian contract research
organisation (CRO) formed two years ago, said it will soon enter
the US market with a new acquisition - the fourth since the
company's creation.
UK biotech firm Acambis has decided to bring the manufacturing of
its soon to be approved smallpox vaccine in-house while its
agreement with contract manufacturer Baxter comes to an end.
In the light of the death of former Russian security agent,
Alexander Litvinenko, pharma companies developing anti-radiation
drugs are increasingly under the spotlight.
Animal welfare group, PETA has reportedly targeted Pfizer, accusing
them of also trying to avoid US animal welfare laws by exporting
its animal testing to countries with no or poor animal welfare
standards.
Charles River Laboratories is the latest in a series of large
contract research organisations making acquisitions to beef up
their Phase I capacity as this market sector remains hot.
As the Asia-Pacific continues to be a hotspot for clinical trials
activity, e-clinical provider ClinPhone has opened its first office
in the region in the hope of gaining a head start.
Merck has been forced to delay marketing plans for its combination
cholesterol drug MK-0524B following problems in formulating its
top-selling statin Zocor (simvastatin) with a new promising
compound under development, MK-524A.
Drug testing services provider Xceleron has set up new facilities
in the US after regulations recently introduced by the Food and
Drug Administration (FDA) are setting this industry sector ablaze.
In the first drug master file (DMF) approval of its kind, the US
Food and Drug Administration (FDA) has approved the sale of
metformin hydrochloride tablets which are produced by an Indian
company using a pharmaceutical formulation...
US generic drugmaker Mylan has agreed to spend around $736m
(€573.4m) to acquire a controlling stake in Matrix, an Indian
manufacturer of active pharmaceutical ingredients (APIs) and solid
oral dosage forms, as relentless competition...
As pharma companies flock towards Eastern Europe and India in a bid
to cut direct clinical trial costs, does outsourcing actually
translate into real world cost-savings?
In what is shaping up to be a new promising area in the
verification of drugs, Analytical Spectral Devices (ASD) has
received another patent for its RxSpec technology which uses near
infrared spectroscopy (IR), as rival company CDEX...
Outsourcing-Pharma: Focus on Phase IIIB-IV research
Phase IIIB-IV clinical research in the US is now booming, growing
20 per cent annually, compared with only 7 per cent for Phase
II-III research, driven by a surge in public drug safety concerns
and increased drug market competitiveness.
A new report has claimed that the benefits pharma crop producers
enjoy have been greatly exaggerated suggesting that any claims
regarding high farmer compensation and booming pharma-crop acreage
are likely overblown.
According to a recent report, analytic separation technology will
continue to evolve as limitations are addressed and standards grow
even more rigorous, as market drivers such as quality control,
instrument design, and software in...
Bangledeshi's Beximco Pharmaceuticals has announced that the
company has raised $21 million after it successfully completed an
institutional placing of global depositary receipts (GDRs).
German packaging company Gerresheimer has announced plans to take
over the pharmaceutical business of troubled Glass Group Inc (GGI)
of the US, after a Delaware bankruptcy court approved the
transaction.
The US market for pharmaceutical packaging will grow by nearly a
third between 2004 and 2011, driven by the increasing demands
placed on packaging by biologic drugs and novel drug delivery
formulations, according to consulting firm...